Approval of Novartis’ ofatumumab delayed by FDA review extension
Novartis submitted the new drug application (NDA) for the drug under FDA’s fast track programme. Credit: Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more